Macupatide and Eloralintide for Weight Management

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Recruiting Phase 2 Interventional Study
Overweight Obesity
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Eli Lilly and Company · Industry
Who this trial is looking for

This trial is looking for adults with obesity or overweight who do not have type 2 diabetes. Participants will take either macupatide and eloralintide together or a placebo for about 64 weeks.

Are You a Good Fit for This Trial?

You may not be able to join if

  • I have type 1 diabetes or type 2 diabetes
  • I have an ongoing history of bradyarrhythmia and/or sinus bradycardia
  • I have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
  • I have a history of acute or chronic pancreatitis
  • All my medications have not been at a stable dose for at least 3 months prior to screening

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have …
Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559

LillyTrials@Lilly.com

CONTACT

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

CONTACT